-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Abivax, Lowers Price Target to $132

Benzinga·06/02/2026 15:09:26
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Abivax (NASDAQ:ABVX) with a Overweight and lowers the price target from $145 to $132.